US
US Carrier Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $1.35 Bn.
Canada at 11.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.60 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.23 Bn | — | — |
| 2025 (base) | $1.35 Bn | +$112.4 Mn | — |
| 2026 (forecast) | $1.47 Bn | +$122.6 Mn | +9.1% |
| 2027 (forecast) | $1.60 Bn | +$133.7 Mn | +19% |
| 2028 (forecast) | $1.75 Bn | +$145.9 Mn | +29.9% |
| 2029 (forecast) | $1.91 Bn | +$159.2 Mn | +41.7% |
| 2030 (forecast) | $2.08 Bn | +$173.7 Mn | +54.6% |
| 2031 (forecast) | $2.27 Bn | +$189.5 Mn | +68.6% |
| 2032 (forecast) | $2.48 Bn | +$206.7 Mn | +84% |
| 2033 (forecast) | $2.70 Bn | +$225.5 Mn | +100.7% |
| 2034 (forecast) | $2.95 Bn | +$246.1 Mn | +119% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$1.35 Bn
China
$250.5 Mn
Canada
$228.6 Mn
Japan
$194.1 Mn
Germany
$112.3 Mn
Brazil
$83.1 Mn
Italy
$80.3 Mn
UK
$77.7 Mn
France
$78.2 Mn
Spain
$54.5 Mn
Ecuador
$53.9 Mn
India
$54.8 Mn
Saudi Arabia
$46.3 Mn
Mexico
$43.9 Mn
New Zealand
$33.1 Mn
Australia
$32.0 Mn
Russia
$26.8 Mn
South Africa
$18.2 Mn
UAE
$15.2 Mn
Egypt
$9.6 Mn
Philippines
$6.8 Mn
Hong Kong
$5.5 Mn
Malaysia
$4.9 Mn
Singapore
$3.7 Mn
Thailand
$3.5 Mn
Kenya
$2.0 Mn
Carrier screening checks future parents for gene changes they could pass on, such as for cystic fibrosis or spinal muscular atrophy.
Key segments of the carrier Screening market include test (Expanded Panels and Targeted Screening) and condition (Cystic Fibrosis, SMA and Thalassemia).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the carrier Screening market.
Routine use of genomics in screening, pharmacy and primary care gives the carrier Screening market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the carrier Screening market.
The carrier Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how carrier Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Carrier Screening right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
From our blog
Pharmaceuticals · US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Digital Health · US
Healthcare Services · US